Public record
Thyroid: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Label
FDA label facts for thyroid
The FDA label read for thyroid (Amerithroid, application ) was last revised on 2026-05-13. It carries no boxed warning. Of the 4 population sections checked, 3 are present: pregnancy, lactation, pediatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2026-05-13 | |
| Label read | Amerithroid | , generic application |
| Boxed warning | No | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Not present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient thyroid from an original manufacturer
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
Medicaid
Medicaid prescriptions for thyroid by state
State Medicaid programmes paid for 18,437 thyroid prescriptions in 2025, with $796,552 reimbursed before rebates. Ohio reported the most (2,083), followed by Pennsylvania (1,510) and California (1,481); 38 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 18,437 | |
| Total reimbursed before rebates, 2025 | $796,552 | |
| States and territories reporting | 38 | with at least one count CMS did not suppress |
| Ohio | 2,083 prescriptions | $97,246 reimbursed |
| Pennsylvania | 1,510 prescriptions | $60,023 reimbursed |
| California | 1,481 prescriptions | $78,596 reimbursed |
| Oregon | 1,154 prescriptions | $40,574 reimbursed |
| Illinois | 1,074 prescriptions | $54,023 reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
All single-ingredient thyroid products in the FDA NDC Directory, fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for thyroid
Retail pharmacies paid an average of $1.20 per unit for THYROID 120 MG TABLET as of 2026-11-11, compared with $1.19 twelve months earlier (+1.3%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| THYROID 120 MG TABLET | $1.20 per unit | 12 months earlier $1.19 (+1.3%) |
| THYROID 15 MG TABLET | $0.5254 per unit | 12 months earlier $0.5206 (+0.9%) |
| THYROID 30 MG TABLET | $0.5997 per unit | 12 months earlier $0.5788 (+3.6%) |
| THYROID 60 MG TABLET | $0.6810 per unit | 12 months earlier $0.6686 (+1.9%) |
| THYROID 90 MG TABLET | $1.03 per unit | 12 months earlier $1.03 (+0.1%) |
| AMERITHROID 120 MG TABLET | $1.20 per unit | no price on file 12 months earlier |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Generic versions of thyroid in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Recalls
FDA drug recalls naming thyroid
FDA enforcement reports list 65 drug recall entries naming thyroid from 2014 to 2026-09-23. 64 of them are for compounded or other unlisted products and 1 for products FDA lists under a label. The most common stated reason was potency out of specification (40 of 65).
| Measure | Value | Note |
|---|---|---|
| Recall entries on record | 65 | |
| For products FDA lists under an approved or registered label | 1 | |
| For compounded or other unlisted products | 64 | matched by the name in the product description |
| Class I (most serious) | 22 | |
| Class II | 43 | |
| Class III | 0 | |
| Most recent recall reported | 2026-09-23 | |
| Most common stated reason | potency out of specification | 40 of 65 entries |
How this was calculated
Counted enforcement report entries matched by FDA's listed active substance, or by the name in the product description where FDA lists none. Reasons were grouped by keywords in FDA's stated reason.
Recalls of single-ingredient thyroid products, plus compounded or unlisted products whose description names it
Each recall covers specific lots from one firm and is not a statement about every product with this ingredient. One event can appear as several entries, one per product.
Articles on Thyroid
- Armour Thyroid International Purchase Legalities: What You Need to Know in 2026
- Armour Thyroid VA Coverage Pathway: How Veterans Can Access Natural Desiccated Thyroid
- Armour Thyroid Cost vs. Alternatives: A Price and Evidence Comparison
- Armour Thyroid Manufacturing, Supply & Shortage History
- Armour Thyroid Regulatory Status: US, EU, Canada, and UK Rules Explained
- Armour Thyroid Compounding Legal Status: FDA History, Label Facts, and What Patients Should Know